Camizestrant + Tamoxifen + Anastrozole + Letrozole + Exemestane + Abemaciclib
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer, Early Breast Cancer
Conditions
Breast Cancer, Early Breast Cancer
Trial Timeline
Oct 5, 2023 → May 6, 2037
NCT ID
NCT05952557About Camizestrant + Tamoxifen + Anastrozole + Letrozole + Exemestane + Abemaciclib
Camizestrant + Tamoxifen + Anastrozole + Letrozole + Exemestane + Abemaciclib is a phase 3 stage product being developed by AstraZeneca for Breast Cancer, Early Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05952557. Target conditions include Breast Cancer, Early Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05952557 | Phase 3 | Recruiting |
Competing Products
20 competing products in Breast Cancer, Early Breast Cancer